Arch Biopartners, Inc. is a portfolio based biotechnology company. It is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The company has five technology platforms which includes: AB569, MetaBlok, Arch Inflammation, Borg:Peptide-Solid Surface Interface and MetaMx. Arch Biopartners was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.
Company profile
Ticker
ACHFF, ARCH
Exchange
Website
CEO
Richard Gabriel Muruve
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Latest filings (excl ownership)
D
$265K in equity / options / securities to be acquired, sold $265K, 6 investors
22 Jan 15
D
$155.52K in equity / options / securities to be acquired, sold $155.52K, 4 investors
18 Aug 14
D
$140K in equity / options / securities to be acquired, sold $140K, 3 investors
4 Apr 14
D
$70K in equity / options / securities to be acquired, sold $70K, 2 investors
6 Mar 14
Latest ownership filings
No filings